The secretome of mesenchymal stromal cells: Role of extracellular vesicles in immunomodulation

Immunology Letters

Volumn 168, Issue 2, 2015, Pages 154-158

  Bruno, Stefania ^a   Deregibus, Maria Chiara ^b   Camussi, Giovanni ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Extracellular vesicles; Immune modulation; Mesenchymal stem cells; Soluble factors

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; MICRORNA; NITRIC OXIDE; PROSTAGLANDIN E2; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CELL COMMUNICATION; CELL FATE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; EXOSOME; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RNA TRANSCRIPTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ANIMALS; CELL COMMUNICATION; EXTRACELLULAR VESICLES; HUMANS; IMMUNE SYSTEM; MESENCHYMAL STROMAL CELLS; SIGNAL TRANSDUCTION;

EID: 84949626635     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.06.007     Document Type: Article

References (71)

1. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012, 10:709-716.
2. Bruno S., Camussi G. Role of mesenchymal stem cell-derived microvesicles in tissue repair. Pediatr. Nephrol. 2013, 28:2249-2254.
3. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
4. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 2002, 30:42-48.
5. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
6. Meisel R., Zibert A., Laryea M., Göbel U., Däubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
7. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
8. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
9. Hwu P., Du M.X., Lapointe R., Do M., Taylor M.W., Young H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 2000, 164:3596-3599.
10. Sato K., Ozaki K., Oh I., Meguro A., Hatanaka K., Nagai T., et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109:228-234.
11. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
12. English K., Barry F.P., Mahon B.P. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol. Lett. 2008, 115:50-58.
13. Djouad F., Charbonnier L.M., Bouffi C., Louis-Plence P., Bony C., Apparailly F., et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007, 25:2025-2032.
14. Chen L., Zhang W., Yue H., Han Q., Chen B., Shi M., et al. Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev. 2007, 16:719-731.
15. Maccario R., Podestà M., Moretta A., Cometa A., Comoli P., Montagna D., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favours the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90:516-525.
16. English K., Ryan J.M., Tobin L., Murphy M.J., Barry F.P., Mahon B.P., et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 2009, 156:149-160.
17. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.
18. Ghannam S., Pène J., Moquet-Torcy G., Jorgensen C., Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 2010, 185:302-312.
19. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
20. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24:386-398.
21. Heijnen H.F., Schiel A.E., Fijnheer R., Geuze H.J., Sixma J.J. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999, 94:3791-3799.
22. Cocucci E., Racchetti G., Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009, 19:43-51.
23. Lötvall J., Hill A.F., Hochberg F., Buzás E.I., Di Vizio D., Gardiner C., et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J. Extracell. Vesicles 2014, 3:26913.
24. György B., Szabó T.G., Pásztói M., Pál Z., Misják P., Aradi B., et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 2011, 68:2667-2688.
25. Ratajczak J., Miekus K., Kucia M., Zhang J., Reca R., Dvorak P., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20:847-856.
26. Aliotta J.M., Sanchez-Guijo F.M., Dooner G.J., Johnson K.W., Dooner M.S., Greer K.A., et al. Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation. Stem Cells 2007, 25:2245-2256.
27. Deregibus M.C., Cantaluppi V., Calogero R., Lo Iacono M., Tetta C., Biancone L., et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007, 110:2440-2448.
28. Yuan A., Farber E.L., Rapoport A.L., Tejada D., Deniskin R., Akhmedov N.B., et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS ONE 2009, 4:4722.
29. Ludwing A.K., Giebel B. Exosome: small vesicles participating in intercellular communication. Int. J. Biochem. Cell Biol. 2012, 44:11-15.
30. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., et al. B lymphocytes secret antigen presenting vesicles. J. Exp. Med. 1996, 183:1161-1172.
31. Bhatnagar S., Schorey J.S. Exosomes released from infected macrophages contain Mycobacterium avium glycopeptidolipids and are proinflammatory. J. Biol. Chem. 2007, 282:25779-25789.
32. Aline F., Bout D., Amigorena S., Roingeard P., Dimier-Poisson I. Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T. gondii infection. Infect. Immun. 2004, 72:4127-4137.
33. Qazi K.R., Torregrosa Paredes P., Dahlberg B., Grunewald J., Eklund A., et al. Proinflammatory exosomes in bronchoalveolar lavage fluid of patients with sarcoidosis. Thorax 2010, 65:1016-1024.
34. Théry C., Duban L., Segura E., Véron P., Lantz O., Amigorena S. Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol. 2002, 3:1156-1162.
35. Escudier B., Dorval T., Chaput N., André F., Caby M.P., Novault S., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J. Transl. Med. 2005, 3:10.
36. Utsugi-Kobukai S., Fujimaki H., Hotta C., Nakazawa M., Minami M. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol. Lett. 2003, 89:125-131.
37. Chaput N., Schartz N.E., André F., Taïeb J., Novault S., Bonnaventure P., et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol. 2004, 172:2137-2146.
38. Hsu D.H., Paz P., Villaflor G., Rivas A., Mehta-Damani A., Angevin E., et al. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J. Immunother. 2003, 26:440-450.
39. Clayton A., Mitchell J.P., Court J., Mason M.D., Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 2007, 67:7458-7466.
40. Poutsiaka D.D., Schroder E.W., Taylor D.D., Levy E.M., Black P.H. Membrane vesicles shed by murine melanoma cells selectively inhibit the expression of Ia antigen by macrophages. J. Immunol. 1985, 134:138-144.
41. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 2002, 195:1303-1316.
42. Huber V., Fais S., Iero M., Lugini L., Canese P., Squarcina P., et al. Human colorectal cancer cells induce T-cell death through release of pro-apoptotic microvesicles: role in immune escape. Gastroenterology 2005, 128:1796-1804.
43. Wieckowski E.U., Visus C., Szajnik M., Szczepanski M.J., Storkus W.J., Whiteside T.L. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J. Immunol. 2009, 183:3720-3730.
44. Ashiru O., Boutet P., Fernández-Messina L., Agüera-González S., Skepper J.N., Valés-Gómez M., et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010, 70:481-489.
45. Liu C., Yu S., Zinn K., Wang J., Zhang L., Jia Y., et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 2006, 176:1375-1385.
46. Yang C., Robbins P.D. The roles of tumor-derived exosomes in cancer pathogenesis. Clin. Dev. Immunol. 2011, 2011:842849.
47. Taylor D.D., Akyol S., Gercel-Taylor C. Pregnancy-associated exosomes and their modulation of T cell signalling. J. Immunol. 2006, 176:1534-1542.
48. Hedlund M., Stenqvist A.C., Nagaeva O., Kjellberg L., Wulff M., Baranov V., et al. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J. Immunol. 2009, 183:340-351.
49. Camussi G., Deregibus M.C., Bruno S., Cantaluppi V., Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010, 789:838-848.
50. Bruno S., Collino F., Deregibus M.C., Grange C., Tetta C., Camussi G. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev. 2013, 22:758-771.
51. Conforti A., Scarsella M., Starc N., Giordia E., Biagini S., Proia A., et al. Microvesicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro. Stem Cells Dev. 2014, 23:2591-2599.
52. Mokarizadeh A., Delirezh N., Morshedi A., Mosayebi G., Farshid A.A., Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol. Lett. 2012, 147:47-54.
53. Eirin A., Riester S.C., Zhu X.Y., Tang H., Evans J.M., O'Brien D., et al. MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells. Gene 2014, 551:55-64.
54. Kim H.S., Choi D.Y., Yun S.J., Choi S.M., Kang J.W., Jung J.W., et al. Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J. Proteome Res. 2012, 11:839-849.
55. Lopatina T., Bruno S., Tetta C., Kalinina N., Porta M., Camussi G. Platelet-derived growth factor regulates the secretion of extracellular vesicles by adipose mesenchymal stem cells and enhances their angiogenic potential. Cell Commun. Signal. 2014, 12:26.
56. Lopatina T., Mazzeo A., Bruno S., Tetta C., Kalinina N., Romagnoli R., et al. The angiogenic potential of adipose mesenchymal stem cell-derived extracellular vesicles is modulated by basic fibroblast growth factor. J. Stem Cell Res. Ther. 2014, 4:245.
57. Bruno S., Grange C., Deregibus M.C., Calogero R.A., Saviozzi S., Collino F., et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J. Am. Soc. Nephrol. 2009, 20:1053-1067.
58. Tomasoni S., Longaretti L., Rota C., Morigi M., Conti S., Gotti E., et al. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 2013, 22:772-780.
59. Du T., Zou X., Cheng J., Wu S., Zhong L., Ju G., et al. Human Wharton jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cells. Stem Cell Res. Ther. 2013, 4:59.
60. Collino F., Deregibus M.C., Bruno S., Sterpone L., Aghemo G., Viltono L., et al. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS ONE 2010, 5(7):e11803.
61. Lee H.K., Finniss S., Cazacu S., Xiang C., Brodie C. Mesenchymal stem cells deliver exogenous miRNAs to neural cells and induce their differentiation and glutamate transporter expression. Stem Cells Dev. 2014, 23:2851-2861.
62. Kosaka N., Iguchi H., Yoshioka Y., Takeshita F., Matsuki Y., Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 285:17442-17452.
63. Zhang B., Yin Y., Lai R.C., Tan S.S., Choo A.B.H., Lim S.K. Mesenchymal stem cells secrete immunologically active exoxomes. Stem Cells Dev. 2014, 23:1233-1244.
64. Lai R.C., Tan S.S., Teh B.J., Sze S.K., Arslan F., de Kleijn D.P., et al. Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int. J. Proteomics 2012, 2012:971907.
65. Mantovani A., Biswas S.K., Galdiero M.R., Sica A., Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 2013, 229:176-185.
66. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 2006, 177:7303-7311.
67. Favaro E., Carapanetto A., Lamorte S., Fusco A., Caorsi C., Deregibus M.C., et al. Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. Diabetologia 2014, 57:1664-1673.
68. Budoni M., Fierabracci A., Luciano R., Petrini S., Di Ciommo V., Muraca M. The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transpl. 2013, 22:369-379.
69. Blazquez R., Sanchez-Margallo F.M., de la Rosa O., Dalemans W., Alvarez V., Tarazona R., et al. Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells. Front. Immunol. 2014, 5:556.
70. de la Rosa O., Lombardo E., Bereza A., Mancheno-Corvo P., Ramirez C., Menta R., et al. Requirement of IFN-γ-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng. A 2009, 15:2795-2806.
71. Kordelas L., Rebmann V., Ludwig A.K., Radtke S., Ruesing J., Doeppner T.R., et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 2014, 28:970-973.